Naveed Akhtar, MD
Cardiovascular Disease · Fayetteville, GANPI 1467711861
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 26.1% of the total. Reporting peaked in 2022 at $332 and has fallen 56.1% since, to $146 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in GA, where the typical reported total is $2,276.
Across 31 payments — averaging $37.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$302
- AstraZeneca$165
- E.r. Squibb & Sons, L.L.C.$142
- Pfizer$95
- Lantheus Medical Imaging, Inc.$93
- Abbott$85
- plus $276 from 9 others
Across 32 payments — averaging $1669.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$53K
What the payments were for
- Food & beverage$1,12097%
- Education$373%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 5 | $302 |
| AstraZeneca | 4 | $165 |
| E.r. Squibb & Sons, L.L.C. | 3 | $142 |
| Pfizer | 2 | $95 |
| Lantheus Medical Imaging, Inc. | 1 | $93 |
| Abbott | 1 | $85 |
| Alnylam Pharmaceuticals Inc. | 3 | $65 |
| Scpharmaceuticals Inc. | 2 | $45 |
| Merck | 2 | $44 |
| Lexicon Pharmaceuticals, Inc. | 2 | $39 |
| Novartis | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Bio Products Laboratory USA, Inc. | 2 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,157 in reported general payments places this provider in the 35th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 56 | $1,537,657 |
| UptraviSelexipag | 45 | $1,122,319 |
| EntrestoSacubitril/Valsartan | 395 | $358,207 |
| JardianceEmpagliflozin | 202 | $226,237 |
| FarxigaDapagliflozin Propanediol | 195 | $160,452 |
| EliquisApixaban | 124 | $140,552 |
| VerquvoVericiguat | 31 | $27,436 |
| XareltoRivaroxaban | 12 | $14,394 |
| Sildenafil Citrate | 19 | $10,453 |
| Praluent PenAlirocumab | 12 | $9,623 |
| DapagliflozinDapagliflozin Propanediol | 12 | $5,831 |
| Bumetanide | 133 | $2,948 |
| Torsemide | 143 | $2,794 |
| Metoprolol Succinate | 310 | $2,755 |
| Midodrine Hcl | 49 | $2,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $95 | $1,678,210180 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $302 | $1,122,31945 claims |
| NovartisEntresto | $20 | $358,207395 claims |
| Boehringer IngelheimJardiance | $19 | $226,237202 claims |
| AstraZenecaFarxiga | $165 | $160,452195 claims |
| MerckVerquvo | $44 | $27,43631 claims |
| Johnson & JohnsonXarelto | $11 | $14,39412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Fayetteville
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Hiren ShahColumbus$166K
- Mani VannanAtlanta$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.